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Vav3 is a phosphorylation-dependent activator of Rho/Rac GTPases that has been implicated in hematopoietic, bone,
cerebellar, and cardiovascular roles. Consistent with the latter function, Vav3-deficient mice develop hypertension,
tachycardia, and renocardiovascular dysfunctions. The cause of those defects remains unknown as yet. Here, we show that
Vav3 is expressed in GABAegic neurons of the ventrolateral medulla (VLM), a brainstem area that modulates respiratory
rates and, via sympathetic efferents, a large number of physiological circuits controlling blood pressure. On Vav3 loss,
GABAergic cells of the caudal VLM cannot innervate properly their postsynaptic targets in the rostral VLM, leading to
reduced GABAergic transmission between these two areas. This results in an abnormal regulation of catecholamine blood
levels and in improper control of blood pressure and respiration rates to GABAergic signals. By contrast, the reaction of
the rostral VLM to excitatory signals is not impaired. Consistent with those observations, we also demonstrate that Vav3
plays important roles in axon branching and growth cone morphology in primary GABAergic cells. Our study discloses
an essential and nonredundant role for this Vav family member in axon guidance events in brainstem neurons that control
blood pressure and respiratory rates.
INTRODUCTION
Vav3 is one of the three members of the Vav family present
in vertebrate species (Bustelo, 2000; Bustelo and Couceiro,
2008). The main known function of these proteins is to act as
GDP/GTP exchange factors for Rho/Rac GTPases, an activ-
ity that allows the rapid transition of Rho/Rac proteins from
the inactive (GDP-bound) to the active (GTP-bound) state
(Bustelo, 2000; Turner and Billadeau, 2002). Because the
activity of Vav proteins is regulated by direct phosphoryla-
tion on tyrosine residues (Bustelo, 2000; Turner and Bil-
ladeau, 2002), the members of this family are crucial for
connecting stimulated receptors with intrinsic or associated
tyrosine kinase activity to Rho/Rac proteins and, thereby, to
assemble downstream pathways involved in cytoskeletal
change, cell cycle transitions, gene expression, and cell type–
specific biological processes such as immune responses to
antigens, phagocytosis, production of reactive oxygen spe-
cies, neuritogenesis, or axon guidance (Bustelo, 2000; Bustelo
and Couceiro, 2008). Adaptor-like functions for Vav proteins
have been also described during the signaling of antigen
receptors (Bustelo, 2001; Saveliev et al., 2009).
Vav3 plays overlapping roles with other Vav family mem-
bers in the hematopoietic system (Fujikawa et al., 2003; Cella
et al., 2004; Gakidis et al., 2004; Pearce et al., 2004; Hall et al.,
2006; Miletic et al., 2007; Pearce et al., 2007), axon guidance of
neuronal subsets (Cowan et al., 2005), and angiogenesis
(Hunter et al., 2006). Recent data also indicate that Vav3
exerts specific signaling tasks on its own, including the
proper maturation and signaling of osteoclasts (Faccio et al.,
2005), timely cerebellar development (Quevedo et al., 2010),
and the regulation of cardiovascular parameters (Sauzeau et
al., 2006; Sauzeau et al., 2007). As a consequence of the latter
function, Vav3/ mice develop tachycardia, a renin/angio-
tensin II (AngII)–dependent hypertension, cardiovascular
remodeling, and renal dysfunctions (Sauzeau et al., 2006).
This phenotype resembles that found in patients with hy-
perkinetic hemodynamics and borderline hypertension
(Julius and Nesbitt, 1996). The cause of the hypertensive
phenotype of Vav3/ mice is as yet unknown. However,
experimental evidence suggest that it may be caused by the
chronic hyperactivation of the sympathetic nervous system
(SNS), because Vav3-deficient mice have tachycardia and
contain abnormal high levels of catecholamines in their
plasma (Sauzeau et al., 2006). These defects, unlike other
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cardiovascular problems that are detected later on, are al-
ready present in new born animals (Sauzeau et al., 2006).
Consistent with an implication of the SNS, the development
of the hypertension, the tachycardia, and the rest of reno-
cardiovascular phenotypes found in Vav3/ mice is
blocked by treatments with propranolol, a -adrenergic an-
tagonist commonly used in antihypertensive therapies
(Sauzeau et al., 2006). To understand the biological problems
associated with this cardiovascular phenotype, we analyzed
further the physiological and biological dysfunctions present in
Vav3-deficient mice. Herein, we show that these animals have
axon guidance defects in a subset of GABAergic cells of the
VLM, a key brainstem center for the modulation of respiratory
activity and, via sympathetic efferents, for the regulation of
several elements of the cardiovascular system such as the heart,
most classes of resistance arterioles, kidneys, and subsets of
adrenal chromaffin cells (Guyenet, 2006).
MATERIALS AND METHODS
Animal Use
Vav3 and Vav2 knockout mice have been described previously (Sauzeau et al.,
2006; Sauzeau et al., 2007). H-RasG12V/Geo knock-in animals were generated by
Dr. M. Barbacid’s lab (CNIO, Madrid, Spain) and reported before (Schuhma-
cher et al., 2008). CD1, wild-type mice were used for gain-of-function exper-
iments in culture. All animal work was carried out following the regulations
set forth by both the CSIC and Salamanca University Animal Care and Use
Committees. Unless otherwise indicated, we routinely used four-month-old
animals for the experiments reported in this work.
Cytoarchitectural Criteria and Terminology
The terminology and abbreviations used for brain nuclei are taken from a mouse
brain atlas (Frankin and Paxinos, 1996). Specifically, we considered the RVLM as
the VLM region that was limited, medially, by the gigantocellular reticular
nucleus and the inferior olive; laterally, by the spinal trigeminal nucleus and
tract; ventrally, by the ventral medullar surface; dorsally, by the ambiguus
nucleus and adjacent reticular formation; caudally, by the rostral pole of the
lateral reticular nucleus; and rostrally, by the caudal pole of the facial motor
nucleus. We considered as CVLM the region immediately caudal to the RVLM
and that localized between the rostral wings of the lateral reticular nucleus.
Microinjection Studies
Four-month-old mice with similar body weight (20–25 g) were anesthetized
with urethane (2 mg/kg body weight, Sigma, St. Louis, MO), cannulated in
the carotid artery to record the evolution of arterial pressure in real time, and
gently placed in a stereotaxic apparatus (Kopf, Tujunga, CA). After exposing
the skull, the position of the head in the stereotaxic equipment was adjusted
under the visual guidance of an operating microscope so that the height of the
skull surface at the bregma and lambda was the same (Frankin and Paxinos,
1996). The interaural and midlines were taken as landmarks for the stereotaxic
coordinates: for the injection in the RVLM, those were 3.05 mm caudal and
0.20 mm ventral to the interaural line and 1.20 mm lateral to the midline. For
injections in the CVLM, the coordinates were 3.45 mm caudal and 0.1 mm
ventral relative to the interaural line and 1.15 mm lateral to the midline. After
selecting the injection area, a window in the occipital bone was drilled, and
bilateral microinjections of buffered vehicle (30 nl), bicuculline (50 pmol in 30
nl, Sigma) and/or L-glutamate (100 pmol in 30 nl, Sigma) were made in the
indicated VLM areas using a glass micropipette (internal diameter 40 m)
glued to a Hamilton syringe. In the case of muscimol (10 pmol in 30 nl,
Sigma), the microinjections were done unilaterally. Experimental conditions
(light, temperature, noises) were always kept constant during the experi-
ments. However, to get the best comparisons, we always performed consec-
utive experiments of a control and a Vav3/ mice in all these studies. The
appropriateness of the coordinates chosen for the stereotaxic analysis was
demonstrated by confirming that, as expected, the microinjection of L-gluta-
mate in the RVLM and CVLM induce antagonistic effects in both the blood
pressure and breathing rate levels. In addition, and to make it sure that the
microinjection was done in the proper brainstem area in each experiment, we
carried out several controls to reconfirm the targeting of the right regions
within the VLM after recording the initial experimental data. First, we intro-
duced the drugs in neighboring areas to the initial injection to confirm that the
physiological response obtained in the cardiovascular and respiratory sys-
tems was restricted to the targeted VLM area (in the case of WT animals) or,
alternatively, to verify that the absence of physiological responses in Vav3/
mice were not due to microinjections made outside the selected VLM site (see
an example in Fig. S5). Second, we microinjected in the targeted regions 30 nl
of a 1% solution of Fast green FCF104022 (Merck, Darmstadt, Germany) and,
after sacrificing the mice, we obtained tissue sections from the brainstem to
verify by direct microscope examination the localization of the marker (see
examples in Figures 5, G and H and 7, E and F).
Tract-Tracing Experiments
Mice were anesthetized with a mixture of diazepam (5 mg/kg, Sigma),
ketamine (50 mg/kg, Sigma), and atropine (1 mg/kg, Sigma). When neces-
sary, additional anesthesia (one-fifth of the initial dose) was administered
during surgery. Anesthetized animals were placed in a stereotaxic frame,
their skulls exposed by a midline scalp incision, and craniotomyzed over the
CVLM injection coordinates (see above). Animals received a single injection
of biotinylated 10,000 Da dextran amine (Molecular Probes/Invitrogen, Carls-
bad, CA) into the CVLM. To this end, a 10% dextran amine solution in saline
buffer was injected iontophoretically with a 10-m internal diameter glass
micropipette using 5-A positive current pulses (7 s on/7 s off) for 15 min.
After this step, mouse scalps were sutured and animals allowed to recover for
10 d. Animals were then perfused with 4% paraformaldehyde, their brains
removed, cryoprotected, and 40-m-thick sections obtained with a freezing
stage sliding microtome (Microm). Free-floating tissue sections were incu-
bated with an avidin-biotin-peroxidase complex (ABC Standard-kit, Vector
Laboratories) and the tracer revealed using as chromogen a solution contain-
ing 3,3 diaminobenzidine tetrahydrochloride and nickel ammonium sulfate.
Sections were finally mounted on slides and subjected to microscopy analysis.
To obtain cytoarchitectonic references, a series of sections were counter-
stained in parallel with 0.1% cresyl violet (Merck). The dextran amine-labeled
fibers, collaterals, and varicosities were studied using a PL Fluotar 40 lens
(Leica, Wetzlar, Germany) attached to a DMRB light microscope (Leica) that,
in turn, was connected to a computer running the Neolucida software (Mi-
croBrightField, Williston, VT). A set of seven sections of the VLM from the
same animal, regularly spaced at 160 m, were drawn and reconstructed in
three dimensions to compare the distribution of dextran amine-labeled fibers
in Vav3/ and control animals. The external contour of medulla, boundaries
of the central canal, as well as the nucleus ambiguus and the needle wound
area were recorded for spatial reference purposes. Chartings of each section
made were plotted, scaled down, and arranged into plates with the Corel-
DRAW X3 software (Corel, Ottawa, Canada). Three-dimensional reconstruc-
tions were displayed and analyzed using the Neuroexplorer program (Mi-
croBrightField).
Isolation and Transfection of Hippocampal GABAergic Cells
Hippocampi from CD1, Vav3/, and Vav3/ mice were obtained (Bamji et
al., 2003; Rico et al., 2004), cells cultured in poly-L-lysine (0.5 mg/ml) and,
when appropriate, transfected as described previously (Chacon et al., 2010).
For gain-of-function experiments, pcDH1-MCS1-EF1-CoGFP vectors (System
Biosciences) encoding either wild-type Vav3 (pCQS1) or a constitutively
active Vav3 protein (1–144 deletion, pCQS3) were transfected at 2 DIV into
ICR hippocampal neurons. As control, we used the empty pcDH1-MCS1-EF1-
CoGFP vector. For loss-of-function experiments, a mammalian plasmid
(pCS2-EGFP; Clontech) encoding the enhanced green fluorescent protein
(EGFP) was transfected into both wild-type and Vav3/ hippocampal cul-
tures. We chose this timing of transfection to specifically interfere with the
elaboration of axons, but not with their initial outgrowth (Chacon et al., 2010).
Cells were examined at 5 DIV. When appropriate, cells were stimulated with
EphrinA1 (5 g/ml, R&D, Minneapolis, MN) for 10 min, fixed, and processed
as above.
Immunocytochemistry of Hippocampal Cultures
For immunocytochemistry, neuronal cultures were fixed with 4% paraformalde-
hyde for 20 min at room temperature, treated with 0.25% Triton X-100 for 10 min,
and blocked in a solution containing 2% normal goat serum (Atom, Barcelona,
Spain) and 2% bovine serum albumin in phosphate-buffered saline solution for
30 min. After overnight incubation at 4°C with primary antibodies, cells were
rinsed with phosphate-buffered saline solution and incubated with Alexa488-,
Alexa594/Alexa555-, or Alexa633 secondary antibodies to either mouse or rabbit
IgGs (Molecular Probes/Invitrogen) for 1 h. Primary antibodies included a
mouse mAb to GAD65 (Sigma), a rabbit polyclonal to GABA (Sigma), and the
home-made rabbit polyclonal antibody to Vav3 (Movilla and Bustelo, 1999).
All pictures were acquired using a DC500 Leica camera attached to a Leica
CTR5000 microscope (Leica Microsystems; 20/0.5 HC PL Fluotar). All im-
ages were captured under the same conditions within each type of experi-
ment. When quantitation was required, selected images were exported to
Image J (National Institutes of Health, NIH software). The longest neurite per
neuron was measured. GABA-positive growth cone areas were calculated by
tracing those structures on the corresponding microscope image. Then, the
percentage of collapsed growth cones was analyzed in pictures taken within
a cross-shape field traced in each experimental coverslip.
Statistical Analysis
Data from Vav3/ and control animals were analyzed using ANOVA (Fig-
ures 1, 4, 7, and left histogram of 8D), 1-tailed Student’s t (Figure 3 and
Supplemental Figures S1–S4), nonparametric Mann–Whiney (right histogram
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of Figure 8, D, F, and left histogram in H), and 2 (Figure 8H, right panel)
tests. Data are given as the mean  the SEM. P values lower than 0.05 were
considered as statistically significant.
Other experimental procedures can be found in the Supplemental Information.
RESULTS
The Vav3-Deficiency Does Not Affect the Mechanoelastic
and Signaling Properties of Blood Vessels
To investigate the cause of the SNS/AngII-dependent hy-
pertension of Vav3-deficient mice, we first focused our at-
tention on the mechanoelastic behavior of blood vessels and
the signaling properties of vascular smooth muscle cells.
Using a number of physiological and signaling experiments,
we found that the high blood pressure and SNS hyperactiv-
ity of Vav3/ mice were not caused by intrinsic mechanical
or signal reactivity problems in arterial vessels (see Supple-
mental Text and Supplemental Figures S1–S3). Furthermore,
we have previously shown that inactivation of the Vav3
gene, unlike the case of the Vav2 locus, does not eliminate
the response of vascular smooth muscle cells to nitric oxide
and, therefore, that these mice have normal vasodilation to
nitric-oxide-dependent stimuli (Sauzeau et al., 2010). Histo-
logical analysis of the adrenal medulla also ruled out the
presence of pheochromocytoma (data not shown), an adre-
nal gland-derived tumor that raises catecholamine levels
and blood pressure in humans (Lenders et al., 2005). These
results, together with the previous observation that the renal
defects of Vav3/ mice were a consequence of the hyper-
tensive condition found in these animals (Sauzeau et al.,
2006), indicated that the origin of the hypertension and SNS
hyperactivity of these animals was not due to peripheral
defects in the renovascular system.
Vav3 Loss Leads to Tachypnea
A more comprehensive characterization of the phenotype of
Vav3/ mice revealed that these animals suffered from
tachypnea under normoxia (Figure 1, A and B). They also
displayed dysfunctional respiratory responses to environ-
mental challenges. Thus, whereas wild-type (WT) animals
responded to hypercapnia with an initial increase in both the
frequency and amplitude of the inspiration/expiration cy-
cles that was followed by a rapid deceleration of breathing
activity (Figure 1C), Vav3/ animals did not change sig-
nificantly their accelerated breathing frequencies through-
Figure 1. Vav3/ mice show abnormal
breathing patterns. (A) Example of representa-
tive real-time recordings of the respiratory fre-
quency of a WT and a Vav3/ mouse. Up-
ward and downward deflections represent
inspiration and expiration movements, respec-
tively. Scale bar, 1 s. (B) Quantitation of respi-
ratory frequency rates in mice of indicated ge-
notypes (n  10–17). bpm, breaths per min;
**p  0.01 compared with control animals or
the indicated experimental pair (in brackets).
NS, not statistically significant. (C) Represen-
tative segments of the breathing response of a
WT and a Vav3/ mouse subjected to hyper-
capnia for the indicated periods of time. Scale
bar, 1 s. Values below each chart indicate the
mean and SEM of the respiratory frequency
and amplitude at the indicated times of the
hypercapnia response (n  6). au, arbitrary
units. *p  0.05; **p  0.01 compared with WT
controls. (D) Comparison of the respiratory fre-
quency (left panel, n  6–9) and mean arterial
pressure (MAP) (right panel, n  6–9) of ani-
mals of the indicated genotypes that were ei-
ther left untreated (U) or treated with captopril
(C) as indicated in Supplemental Materials and
Methods. **p  0.01 compared with either un-
treated WT controls or the indicated experi-
mental pair (in brackets).
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out the hypercapnic conditions (Figure 1C). Several obser-
vations demonstrated that the tachypnea, unlike other
dysfunctions found in these animals (Sauzeau et al., 2006),
was not due to the hypertensive state present in these ani-
mals. Thus, we observed that Vav2/ knockout and
H-RasG12V/G12V knock-in animals, two mouse strains that
develop an AngII-dependent hypertensive state (Sauzeau et
al., 2007; Schuhmacher et al., 2008), had normal breathing
rates under both normoxic (Figure 1B) and hypercapnic
conditions (data not shown). Furthermore, we found that a
long-term treatment with captopril, a drug that blocks AngII
biosynthesis and the hypertensive state of Vav3/ mice
(Figure 1D) (Sauzeau et al., 2006), did not have any effect in
the tachypnea present in Vav3-deficient animals (Figure 1D).
Additional experiments ruled out that the hypercapnia
could induce the hypertension of Vav3/ animals due to
defective O2/CO2 exchange in their lungs (see Supplemental
Text, Supplemental Table S1, and Supplemental Figure S4).
These results indicate that the Vav3 mutation leads to gen-
eral, mutually independent dysfunctions in the control of
blood pressure and respiratory rates.
Vav3 Is Expressed in GABAergic Cells of the Ventrolateral
Medulla
The simultaneous development of chronic sympathoexcita-
tion, tachycardia, systemic hypertension, and tachypnea in
Vav3-deficient mice suggested that they probably had a
neurogenic defect in regulatory centers controlling sympa-
thetic outflow as well as cardiovascular and respiratory
activities. To shed light on the possible origin of the pheno-
type of Vav3/ mice, we next performed expression stud-
ies to localize the sites of expression of the Vav3 proto-
oncogene in mouse tissues. These analyses indicated that
Vav3 was present in cerebellar granular and Purkinje cells
(Quevedo et al., 2010), scattered neurons of the prefrontal
cortex, and GABAergic cell populations of the hippocampus
(see below, Figure 8, A and B). Interestingly, Vav3 was
detected at high levels in both the rostral (RVLM) and cau-
dal (CVLM) parts of the VLM (Figure 2), a brainstem center
involved in the regulation of heart, vascular, and respiratory
activity (Bianchi et al., 1995; Richter and Spyer, 2001; Guy-
enet, 2006). To ensure properly balanced physiological re-
sponses, the sympathetic outflow of RVLM neurons is regu-
lated by GABAergic (inhibitory) and glutamatergic (excitatory)
inputs (Guyenet, 2006). The inhibitory inputs on the RVLM
emanate primarily from GABAergic neurons present in the
CVLM whereas the glutamatergic signals derive form other
brain areas (Blessing, 1988; Thrasher, 2005; Guyenet, 2006).
Within the VLM, we detected high levels of Vav3 protein
(Figure 2, A–D) and Vav3 mRNA (Figure 2C) in somas of
CVLM cells. We could not detect the Vav3 transcript in the
RVLM (Figure 2C). However, we did observe that its encoded
Figure 2. Expression of Vav3 in the VLM. (A
and B) Representative examples of coronal
brainstem sections containing either the CVLM
(A) or the RVLM (B) that were processed to
detect the expression of the Vav3 proto-onco-
gene. On the left side of each panel, selected
anatomical areas have been highlighted. Amb,
nucleus ambiguus; CC, central canal; LPGi, lat-
eral paragigantocellular nucleus; PY, pyrami-
dal tract; Sp5I, spinal trigeminal nucleus inter-
polar. VLMs are shaded on gray. In the right
side of each panel, we show a hematoxylin-
eosin stained section incubated with anti-Vav3
antibodies. *nonspecific signal; D, dorsal; V,
ventral. Squares show areas considered to con-
tain the CVLM (A) and RVLM (B). Scale bar, 1
mm. (C) Detection of either Vav3 protein (left
panels) or Vav3 mRNA (rest of panels) in VLM
areas from mice of the indicated genotypes.
Scale bar, 100 m. Ab, antibody; cRNA, anti-
sense cRNA probe; L, lateral. (D) Colocaliza-
tion of Vav3 (green, left panels) with GAD65
and GAD67 (red, middle panels) in the indi-
cated VLM areas by confocal immunofluores-
cence. Areas of colocalization are shown in
yellow (right panels). Scale bar, 10 m.
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product displayed a characteristic punctate pattern in that re-
gion (Figure 2, C and D). These signals were not seen in
sections from Vav3/ mice (Figure 2C), demonstrating they
were specific for Vav3. Vav3 colocalized with the GABAergic
markers GAD65 and GAD67 in the cytosol of cells present in
the CVLM (Figure 2D). In the RVLM, Vav3 also colocalized
with GAD65, a marker for presynaptic GABAergic terminals,
in vesicle-like structures (Figure 2D). These results indicate that
the expression of Vav3 is restricted to the somas and axon
terminals of CVLM GABAergic neurons, the cell type of the
CVLM that relays both tonic and baroreceptor-dependent in-
hibitory signals to RVLM cells (Guyenet, 2006).
Defective GABAergic Responses in the Ventrolateral
Medulla of Vav3/ Mice
In light of the above expression profile, we decided to study the
functional status of the VLM in Vav3/ mice. Using immu-
nofluorescence techniques, we observed a marked reduction
(	50%) in the expression of specific GABAergic axon terminal
markers, including GAD65 (Figure 3, A and B) and v-GAT
(Figure 3, A and B) in the RVLM of Vav3/ mice when
compared with WT animals. In contrast, we did not detect any
change in the expression of GABAA receptors in this area
(Figure 3, A and B). In agreement with the loss of inhibitory
synapses, immunohistochemical analyses revealed that the
RVLM of Vav3/ animals contained neurons with higher
levels of tyrosine hydroxylase immunostaining density than
those from control mice (Figure 3, B–D), a clear indication of
catecholaminergic hyperactivity in the RVLM of Vav3-deficient
animals. These results suggested that the up-regulation of the
SNS found in Vav3/ mice might derive from the reduction
in the number of GABAergic inputs that exert inhibitory mod-
ulation on postsynaptic RVLM cells.
To validate this hypothesis, we tested in vivo the
GABAergic and glutamatergic responses of the VLM using
stereotaxic methods. The stereotaxic coordinates selected for
the RVLM and CVLM in these experiments (see Materials
and Methods) were accurate, as demonstrated by the ex-
pected responses induced by microinjections of L-glutamate
in the RVLM (increase in blood pressure and breathing
frequency; see Supplemental Figure S5, A–C), CVLM (reduc-
tion in blood pressure and bradypnea, see Supplemental
Figure 3. Vav3 affects the number of GABAergic inputs in the RVLM. (A) Detection of GAD65 (top panels), v-GAT (middle panels), and
GABAA receptor (GABA-R, bottom panels) in WT (left panels) and Vav3/ (right panels) RVLMs using immunofluorescence techniques.
Cell nuclei were visualized using DAPI. Scale bar, 40 m. (B) Intensity levels of the signals for each maker in the RVLM sections from mice
of the indicated genotypes (n  7–10). **p  0.01 compared with WT controls. (C and D) Top, expression of tyrosine hydroxylase in coronal
sections of the brainstem containing the RVLM from WT (C) and Vav3/ (D) mice. Sections were taken serially from a more rostral (left)
to a more caudal (right) position within the RVLM. Bottom, representative coronal brainstem sections from a WT (C) and a Vav3/ (D)
mouse. The position of these sections is the same to those shown in the third panel displayed at the top. Abbreviations of brainstem areas
are the same used in the legend to Figure 2. Scale bars: 100 m (top panels) and 1 mm (bottom panels).
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Figure S5, D–F), and in an area outside the VLM (no effect on
those two parameters, see Supplemental Figure S5, G–I) of
WT mice. We then microinjected in the RVLM bicuculline, a
GABAA receptor inhibitor that promotes high blood pres-
sure and accelerated breathing by blocking the inhibitory
effects of GABA on RVLM neurons (Yoshida et al., 2002). We
reasoned that if our hypothesis were correct, Vav3/ ani-
mals would show a reduced response to bicuculline when
compared with their normal littermates. The microinjection
of this drug in the RVLM induced a rapid and transient in-
crease in both the blood pressure (Figure 4, A and B) and
breathing frequency (Figure 4, C and D) in WT but not Vav3
null animals. The plasma concentration of SNS-derived nor-
adrenaline and adrenaline also increased in Vav3/ mice
(Figure 4, E and F) but either did not change (in the case of
noradrenaline, Figure 4E) or increased to a much lower extent
(in the case of adrenaline, Figure 4F) in Vav3/ animals under
these experimental conditions, further demonstrating that the
GABAergic responsiveness of the RVLM was altered in Vav3-
deficient mice. By contrast, we observed that the subsequent
microinjection of L-glutamate in the same brainstem region
promoted surges in the blood pressure (Figure 4, A and B) and
breathing frequency (Figure 4, C and D) in animals of both
genotypes, indicating that the response of VLM cells to this
neurotransmitter was not altered in the knockout animals. We
also observed that Vav3/ and control animals reacted to
microinjections of L-glutamate alone in the RVLM with in-
creases in blood pressure, breathing rates, and catecholamine
plasma levels (Supplemental Figure S5, A–C and data not
shown). Despite this, we routinely observed that the high
blood pressure generated under these conditions lasted twice
as long in Vav3-deficient mice than in WT animals (Figure 4G),
Figure 4. GABAergic signal defects in the RVLM of Vav3/ mice. (A) Representative real-time recordings of the blood pressure levels of
a WT (red, left panel) or a Vav3/(blue, right panel) mouse upon bilateral microinjections of bicuculline (B) and L-glutamate (G) in the
RVLM. The time of injection is indicated by arrows. Brackets (labeled 1–4) shown at the bottom of charts indicate the time intervals for the
breathing recordings shown in C. Intervals 2 and 4 were also used to measure the drug-induced arterial pressure shown in panel B. Scale
bar, 2 min. (B) Arterial pressure levels in animals of the indicated genotypes microinjected in the RVLM with bicuculline (B) and L-glutamate
(G) or with placebo (P) (n  5–6). *p  0.05; **p  0.01 compared with either the untreated WT controls or the indicated experimental pair
(in brackets). (C) Example of representative real-time recordings of the respiratory frequency of a WT (red, left panel) and a Vav3/ (blue,
right panel) mouse at the times indicated in panel A. (D) Breathing frequency in mice of the indicated genotypes subjected to the
microinjections shown in B (n  5–6). *p  0.05; **p  0.01 compared with either the untreated WT controls or the indicated experimental
pair (in brackets). (E and F) Bicuculline-dependent variations in the plasma levels of noradrenaline (E) and adrenaline (F) in mice of the
indicated genotypes (n  5). *p  0.05; **p  0.01 compared with either untreated WT animals or the indicated experimental pair (in
brackets). (G) Time of recovery of the blood pressure upon the bilateral microinjection of L-glutamate in the RVLM of mice of the indicated
genotypes (n  5–6). **p  0.01 compared with WT control.
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suggesting that the L-glutamate excitatory effect in the RVLM
was not counterbalanced adequately by GABAergic signals in
the case of Vav3/ mice.
The functionality of postsynaptic GABA receptors was not
affected in the RVLM of Vav3-deficient mice, because we
observed a similar drop in blood pressure (Figure 5, A and
B) and breathing frequency (Figure 5, C and D) in Vav3/
and WT animals upon the microinjection of muscimol, a
GABA receptor agonist, in the RVLM. These results are
consistent with the prior observation that RVLM neurons
have normal levels of GABAA receptors in Vav3/ animals
(see above, Figure 3, A and B). Supporting the hypothesis
Figure 5. Normal response of the RVLM of Vav3/ mice to muscimol. (A) Representative real-time recordings of blood pressure levels in
a WT (red, left panel) or a Vav3/ (blue, right panel) mouse upon unilateral microinjections of muscimol (M) in the RVLM. The time of
injection is indicated by arrows. Brackets (labeled 1–3) shown at the bottom of charts indicate the time intervals for the breathing recordings
shown in C. Segments 2 were also used to measure the drug-induced arterial pressure shown in panel B. Scale bar, 2 min. (B) Arterial pressure
levels in animals of the indicated genotypes microinjected in the RVLM with muscimol (M) or placebo (P) (n  5–6). *p  0.05; **p  0.01
compared with either untreated WT mice or the indicated experimental pair (in brackets). (C) Example of representative real-time recordings
of the respiratory frequency of a WT (red, left panel) and a Vav3/ (blue, right panel) mouse at the times indicated in panel A. (D) Breathing
frequency of mice of the indicated genotypes subjected to the microinjections indicated in B (n  5–6). *p  0.05; **p  0.01 compared with
either untreated WT control or the indicated experimental pair (in brackets). (E and F) Muscimol-dependent variations in the plasma levels
of noradrenaline (E) and adrenaline (F) in mice of the indicated genotypes (n  5). *p  0.05; **p  0.01 compared with either untreated WT
mice or the indicated experimental pair (in brackets). (G and H) Example of the appropriate localization of the microinjected Fast green
FCF104022 marker in the RVLM of a Vav3/ mice. A Fast green solution (30 nl) was microinjected in the RVLM of mice. After euthanasia,
coronal brainstem sections containing either the RVLM (G) or the CVLM (H) were generated and processed to detect Fast green signals. A
schematic representation of the brainstem in those sections has been included in the panels for reference purposes. Abbreviations of
brainstem areas are the same used in the legend to Figure 2. Scale bars, 0.5 mm.
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that the sympathoexcitation is a downstream effect of the
deregulated activity of the RVLM, we observed that
the microinjection of muscimol in this region eliminated
the high levels of catecholamines present in the plasma of
Vav3-deficient mice (Figure 5, E and F). In addition to the
expected physiological responses obtained with the micro-
injection of L-glutamate and muscimol in the RVLM of
Vav3/ mice (see above), the injection of the Fast green
FCF104022 marker confirmed that the microinjections did
target the RVLM and not other cardiorespiratory centers in
the brainstem such as the CVLM (Figure 5, G and H). Taken
together, these results indicate that the RVLM of Vav3/
mice does not respond correctly to GABAergic inhibitory
inputs that modulate catecholamine production, blood pres-
sure, and respiratory activity.
Abnormal GABAergic Connectivity between the CVLM
and RVLM
The reduction of GABAergic inputs and the dysfunction of
GABAergic-mediated responses in the RVLM of Vav3/
animals could be due to a reduction in the number of
GABAergic CVLM neurons, to axon guidance defects,
and/or to improper synapse formation by the GABAergic
axons once they reached the bulbospinal VLM postsynaptic
targets. To identify the cause of the GABAergic dysfunction
present in Vav3/ mice, we first evaluated by immunohis-
tochemistry the relative numbers of GABA-positive cells in
the VLM of both Vav3-deficient and control animals. These
experiments revealed similar densities of GABA-positive
cells in the VLMs regardless of the genotype of the animals
examined (Supplemental Figure S6), indicating that the de-
velopment, survival, and/or migration of GABAergic cells
to the CVLM was not grossly affected by the loss of Vav3
gene expression.
To investigate the status of the GABAergic axon projec-
tions from the CVLM to the RVLM, we next introduced
biotinylated dextran amine, a predominantly anterograde
neurotracer (Reiner et al., 2000), in CVLM-localized cells
using iontophoretic techniques. After a period of recovery to
allow the migration of the tracer along the axons of the
iontophoresed cells, we killed the animals and studied the
localization of dextran amine-labeled axon fibers and termi-
nals in serial brainstem sections. Costaining of some of those
sections with GABAergic markers (GAD65 and GAD67)
demonstrated that the neurotracer was effectively intro-
duced in a significant fraction of CVLM GABAergic cells
(Supplemental Figure S7). As expected, the tracer was also
introduced in non-GABAergic cells (Supplemental Figure
S7). In WT animals, we observed that the tracer migrated
from the injection site to the RVLM following both ipsilat-
eral and contralateral routes (Figure 6, A and B). This bilat-
eral migration pattern is consistent with previously analysis
conducted in the VLM using axon tract-tracing and physio-
logical methods (Li et al., 1991; Masuda et al., 1991; Schre-
ihofer and Guyenet, 2003). Other rostral and caudal projec-
tions from the injection site were also observed (Figure 6, A
and B and Supplemental Text), a result that confirms previ-
ous data indicating that CVLM neurons establish connec-
tions with several regions of the brainstem (see Supplemen-
tal Text). We observed the same migration routes for the
Figure 6. Defects in axon guidance in the VLM of Vav3/ mice. (A) Distribution of dextran amine-labeled fibers (lanes) and buttons (dots)
in coronal brainstem sections derived from mice of the indicated genotypes. Sections shown were taken in the original dextran amine injection
site (II) as well as in either more caudal (I) or rostral (III–V) positions from that injection site (n  4 in each group). Scale bar, 500 m. The
area shaded on black in section II marks the neurotracer injection site. The area shaded on gray indicated the position of the nucleus ambiguus
used for orientation purposes. The coordinates of each section are indicated on the right. (B) 3D reconstruction of the trajectory and
localization of dextran amine-labeled fibers (black) and buttons (red dots). A frontal (upper panels), a 45° rotation to the left (middle panels),
and a 45° rotation to the right (bottom panels) view is displayed for each data group collected from WT (left column) and Vav3/ (right
column) mice. The injection site (black sphere), the nucleus ambiguus (gray cylinders), and the external contour and central canal (blue) have
been highlighted in all 3D reconstructions. Scale bar, 500 m.
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neurotracer in the case of brainstem sections obtained from
Vav3/ mice. However, we reproducibly detected in this
case a reduced number of dextran amine-positive buttons in
sections located before and on the RVLM itself (Figure 6, A
and B). Several observations indicated that this was not due
to less effective iontophoretic efficiencies of the experiments
involving knockout animals. First, we consistently observed
the same reduction in four independent tract-tracing exper-
iments. Second, we observed that the reduction in buttons
and fibers did not affect other regions of the Vav3/ brain-
stem. For example, we reproducibly observed a significant
increase in the number of dextran amine-positive buttons in
sections located caudally to the injection site in Vav3-defi-
cient mice when compared with samples from control ani-
mals (Figure 6, A and B; top panels on the right). Likewise,
we observed an increase in the number of dextran-amine–
labeled fibers crossing between the ipsilateral and contralat-
eral injection side in sections immediately rostral to the
injection site in Vav3/ animals relative to WT mice (Figure
6A, third and fourth panels from top). We also confirmed by
histological analysis that the scar of the needle used for the
iontophoresis was accurately located in the CVLM (Figure
6A, second panels from top). These observations indicate
that the loss of Vav3 induces improper innervation of the
RVLM postsynaptic targets by CVLM GABAergic cells.
To corroborate the above data with independent tech-
niques, we decided to record the transmission of GABAergic
signals from the CVLM to the RVLM. To this end, we took
advantage of previous observations indicating that the ad-
dition of L-glutamate stimulates the GABAergic cells
present in the CVLM (Tolentino-Silva et al., 2000). Consistent
with this, we observed that microinjections of L-glutamate
in the CVLM induced a rapid, but transient reduction in the
blood pressure (Figures 7, A and B, and Supplemental Fig-
Figure 7. Defects in GABAergic transmission in the VLM of Vav3/ mice. (A) Representative real-time recordings of blood pressure levels
of a WT (red, left panel) or a Vav3/ (blue, right panel) mouse upon a bilateral microinjection of L-glutamate (G) in the CVLM. The time
of each microinjection is indicated by arrows. Brackets (labeled 1–3) shown at the bottom of charts indicate the time intervals for the breathing
recordings shown in C. Segments 2 were also used to measure the drug-induced arterial pressure shown in panel B. Scale bar, 2 min. (B)
Arterial pressure levels in animals of the indicated genotypes microinjected in the CVLM with L-glutamate (G) or placebo (P) (n 5–6). *p
0.05; **p  0.01 compared with either untreated WT mice or the indicated experimental pair (in brackets). (C) Example of representative
real-time recordings of the respiratory frequency of a WT (red, left panel) and a Vav3/ (blue, right panel) mouse at the times indicated in
panel A. Scale bar, 2 s. (D) Breathing frequency in mice of the indicated genotypes microinjected in the CVLM with either L-glutamate (G)
or placebo (P) (n 5–6). *p 0.05; **p 0.01 compared with either untreated WT mice or the indicated experimental pair (in brackets). (E,F)
Example of the appropriate localization of the microinjected Fast green FCF104022 marker in the CVLM of a Vav3/ mice. On microinjection
of the marker, coronal brainstem sections containing the RVLM (E) and the CVLM (F) were obtained and processed as indicated in Materials
and Methods. Abbreviations of brainstem areas are the same used in the legend to Figure 2. Scale bars, 0.5 mm.
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Figure 8. Vav3 controls axon growth and branching in GABAergic cells. (A and B) Detection of the indicated proteins (top) in WT hippocampal
GABAergic neurons in culture by either standard (A) or confocal (B) microscopy. Signals derived from Vav3 are shown in green (A and B; left and right
panels). Phalloidin (A) and GAD65 (B) staining are shown in red (middle and right panels). Areas of colocalization of Vav3 with the other two proteins
are shown in yellow (A and B; right panels). GC, growth cone (A). Arrowheads indicate the localization of Vav3 in tips of filopodia (B). Scale bar, 5 m.
(C) Composite images and representative drawings of 5 DIV WT GABAergic hippocampal neurons (red) that were mock-transfected (left panel) or
transfected with plasmids encoding the indicated Vav3 proteins (top). Scale bars, 40m (images) and 80m (drawings). (D) Quantification of the longest
neurite length per neuron (n  99 neurons, three independent experiments) (left panel) and of number of branches per neuron (n  99 neurons, three
independent experiments) (right panel). *p 0.05; **p 0.01 compared with either mock-transfected cells or the indicated experimental pair (in brackets).
(E) Composite images and representative drawings of WT (left panel) and Vav3-deficient (right panel) hippocampal GABAergic neurons (identified in red
using anti-GABA antibodies). Scale bar as in B. (F) Quantification of the longest neurite length per neuron (n  104 neurons, three independent
experiments) (left panel) and of branches per neuron (n 104 neurons, three independent experiments) (right panel). *p 0.05 compared with WT cells.
(G) Images of WT (upper panels) and Vav3-deficient (lower panels) hippocampal GABAergic growth cones upon incubation of 5 DIV cell cultures with
either control (left panels) or EphrinA1-containing (right panels) media for 10 min. Scale bar, 5 m. (H) Quantification of the growth cone area (n 546
growth cones, three independent experiments) (left panel) and collapse (n 546 growth cones, three independent experiments) (right panel) in the total
population of neurons identified as GABA positive neurons in the indicated culture conditions. **p  0.01; ***p  0.01 compared with the indicated
experimental pair (in brackets).
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ure S5E) and respiratory activity (Figures 7, C and D and
Supplemental Figure S5F) of WT animals. By contrast, the
microinjection of this neurotransmitter had no significant
effects in the blood pressure (Figure 7, A and B) and breath-
ing rates (Figure 7, C and D) of Vav3/ mice, further
supporting the lack of proper GABAergic innervation of the
RVLM by the CVLM in those mice. Subsequent controls
microinjecting the Fast green FCF104022 marker in the
CVLM confirmed the correct targeting of this region in the
sterotaxic experiments (Figure 7, E and F). Taken together,
our results demonstrate that the CVLM GABAergic axons
do not reach their target in absence of Vav3, suggesting that
this GEF may be involved in the axon growth and/or guid-
ance of these GABAergic inputs.
Vav3 Controls Axon Growth and Branching
Due to the fact that GABAergic VLM cells cannot be isolated
and cultivated in vitro, we resorted to the use of GABAergic
neurons from the hippocampus as a model to investigate the
specific implication of Vav3 in axonal development. Vav3 is
expressed endogenously in axons (Figure 8, A and B),
growth cones (Figure 8, A and B), and tips of growth cone
filopodia (Figure 8B) of hippocampal neurons, suggesting
that this strategy may be an amenable way of investigating
the role of this GEF in axon behavior. Using transient trans-
fections, we observed that the overexpression of either full-
length Vav3 or an N-terminally truncated, constitutively
active Vav3 mutant protein in WT GABAergic neurons in-
duces an increase and a reduction of maximal axon length
and branch number, respectively (Figure 8, C and D). Using
hippocampal cultures obtained from control and Vav3/
mice, we also observed that the Vav3 deficiency led to an
increase in the number of spontaneous axon branches in
GABAergic cells (Figure 8, E and F) and to a reduction of
growth cone areas (Figure 8, G and H). By contrast, it did not
have any impact on the length of the longest axon (Figure 8,
E and F), indicating that the positive effect induced by the
constitutively active version of Vav3 in this response (see
above, Figure 8D) is a gain-of-function effect or, alternatively,
that a redundant Rho/Rac GEF can still ensure proper axon
outgrowth when endogenous Vav3 is missing. Altogether,
our results indicate that Vav3 is primarily required for nor-
mal axonal branching and growth cone formation, suggest-
ing that retraction and/or inhibition of novo collateral ex-
tension is altered in absence of the GEF protein.
Vav family proteins have been associated with Eph recep-
tor-dependent repulsion processes in mouse retinal ganglion
cells. Such implication appears to be highly specific, because
no defects have been observed in Semaphorin/plexin-de-
pendent growth cone collapse in the same cell setting
(Cowan et al., 2005). To verify whether Vav3 could be in-
volved in a similar pathway in GABAergic hippocampal
neurons, we measured the growth cone collapse response of
WT and Vav3-deficient hippocampal neurons upon stimu-
lation with EphrinA1, a ligand for EphA family receptors.
Vav3-deficient cells were less responsive than WT cells in
this assay (Figure 8H, right panel). Taken together, these
results indicate that Vav3 is important for the regulation of
axon branching and growth cone morphology as well as for
Ephrin-dependent axon collapsing responses in GABAergic
cells.
DISCUSSION
In this work, we have shown that the cardiovascular defects
found in Vav3-deficient mice are not caused by alterations in
the intrinsic mechanoelastic and signaling properties of the
vascular system or to tumorigenic processes in peripheral
SNS areas such as the adrenal gland medulla. Consistent
with the detection of tachycardia and chronic sympathoex-
citation in those mice (Sauzeau et al., 2006), our data indicate
that the hypertension of Vav3/ mice stems from a neuro-
genic defect probably located in the VLM. Using a combi-
nation of tract-tracing, immunohistochemical, and stero-
taxic-based physiological experiments, we have shown that
GABAergic neurons located in the CVLM of Vav3-deficient
mice cannot reach efficiently their postsynaptic RVLM tar-
gets and that, consequently, the GABAergic transmission
between the ventral and caudal parts of the VLM is impaired
(Figure 9). Further support for the deregulated activity of
this region in Vav3-deficient mice comes from the immuno-
histochemical data indicating the presence of hyperactivated
sympathetic cells in their RVLMs and, in addition, by the
observation that the plasma catecholamine levels drop to
physiological concentrations in these animals when their
defective GABAergic response is rescued by the microinjec-
tion of GABA receptor agonists in the RVLM. The GABAer-
gic CVLM-RVLM connection represents a critical regulatory
point to control sympathetic outflow from the VLM, because
CVLM neurons feed tonic inhibitory signals to the RVLM
and, at the same time, relay afferent signals derived from
peripheral baroreceptors to that brainstem area (Guyenet,
2006). These two activities act coordinately to ensure the
rapid restoration of normotensive values upon sporadic
changes in blood pressure and, in addition, to reset the
threshold for the activation of the baroreflex by RVLM cells,
an action that in turn facilitates adaptative rises of blood
pressure to new environmental, health or physiological con-
ditions (Guyenet, 2006). Consistent with the role of VLM in
the coordination of breathing activity via the adjacent Pre-
Bo¨tzinger complex, a brainstem area rostrally adjacent and
overlapping to the RVLM (Bianchi et al., 1995; Richter and
Spyer, 2001), we have also observed that Vav3-deficient mice
have alterations in the breathing activity that lead to chronic
tachypnea (Figure 9).
Given that the nature and cytological complexity of the
VLM is not compatible with mechanistic, cell biology-based
experiments with cultured primary cells, we cannot discern
at this moment the biological process impaired in Vav3/
CVLM GABAergic cells. To bypass this hurdle, we have
Figure 9. Summary of the results obtained in this work. Inhibitory
and stimulatory actions are shown as blunted lines and arrows,
respectively. Broken lines indicate disrupted axonal connections.
Conditions present in WT and Vav3-deficient mice are shown in the
left and right panel, respectively. See further details in main text.
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used hippocampal GABAergic neurons as a model to obtain
indirect information about the role of Vav3 in axon guid-
ance-related processes. We have observed using this system
that Vav3 is important for axonal arbor remodeling, for
proper growth cone size, and for Ephrin/Eph receptor-me-
diated growth cone collapse responses, three critical steps
that contribute to proper axon guidance that are under the
control of Rho/Rac family proteins (Govek et al., 2005). An
implication of Vav3 and Vav2 in Ephrin-mediated growth
cone collapse has been reported before in retina ganglion
cells (Cowan et al., 2005). This function is relevant for axon
guidance, because Vav2/;Vav3/-deficient mice show
defects in ipsilateral retinogeniculate projections (Cowan et
al., 2005). However, unlike our case, this group has not
found any defect in growth cone shape and axon branching
in Vav2/;Vav3/ retina ganglion cells (Cowan et al.,
2005). A plausible explanation for this discrepancy is that
Vav3 may be required for normal growth cone shape only
when neurons are cultured in poly-L-lysine alone, as previ-
ously described for other neuronal cultures (Chacon et al.,
2010). Alternatively, the neuron type used or the presence of
other redundant Rho/Rac GEFs in retina ganglion cells may
also explain this experimental discrepancy. Interestingly, it
has been recently shown that D. melanogaster Vav protein
also plays critical roles in axon guidance during late embry-
ogenesis (Malartre et al., 2010). The general implication of
those Vav family members in general axon guidance pro-
cesses in different neuronal subtypes suggest that Vav3 may
also play similar functions in GABAergic VLM cells.
To date, the implication of the VLM in the long-term
control of blood pressure has been based only in indirect
short-term experiments carried out with fresh tissue sections
or with anesthetized animals (Guyenet, 2006). Indeed, to our
knowledge, the only clear link between the VLM and sus-
tained blood pressure changes has been the observation that
the adenoviral-mediated overexpression of endothelial nitric
oxide synthase in the VLM induces transient bradycardia
and low blood pressure levels in rats during a 5- to 10-d-long
period postinfection (Kishi et al., 2001; Kishi et al., 2002), an
effect attributed to an increase in GABA release induced by
the local production of nitric oxide in this region (Kishi et al.,
2001). Our data complement these previous results by show-
ing that the removal of GABAergic signaling leads to hyper-
tension and, in addition, that the loss of blood normotensia
can be sustained throughout the life of the investigated
animals.
In summary, our results provide evidence for the impli-
cation of Vav3 in axon guidance events and in cardiorespi-
ratory regulation, for the role of the VLM in long-term blood
pressure control and, perhaps more importantly, suggest
that some cases of neurogenic hypertension can derive from
abnormal functioning of brain centers that feed tonic inhib-
itory signals into the RVLM. It would be important therefore
revisiting the status of VLM regions in hypertension to
verify whether alterations in that area may contribute to the
origin of some neurogenic hypertension cases. Based on our
data, hypertensive patients with associated tachycardia or
with a previous history of borderline hypertension in their
youth would be the best population groups to look at. The
progressive and step-wise evolution of the sympathetic and
cardiovascular dysfunctions developed in Vav3/ mice
also offers new possibilities for studying the evolution of
additional SNS-dependent events and for dissecting in more
detail the multiple synergistic cross-talk established by
physiological circuits and tissues in cardiovascular disease.
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